bluebird bio Manufacturing
Durham, NC
In-house manufacturer
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
70.5
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (11)
○ Press
○ EMA GMP
○ MHRA GMP
✓ HC GMP (1)
Quick Facts: bluebird bio Manufacturing
- Signal Score
- 70.5/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Durham, NC
- Modalities
- Lentiviral, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About bluebird bio Manufacturing
Manufactures Zynteglo and Lyfgenia gene therapies.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Most Recent HC OutcomeCompliant · 2021-03-01
HC Attribution1 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesLentiviral, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
11 SEC filings with industry mentions on record (shown, not scored)
SEC Filings11 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity
58.0
1 manufacturing site: Durham, NC
Modalities: Lentiviral, Cell Therapy
Capacity assessment: 58.0/100
Sites: Durham, NC
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Durham, NC
Modalities: Lentiviral, Cell Therapy
Capacity assessment: 58.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (13 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the careers board covers the whole biotech, and its manufacturing roles can't be separated reliably. We'd rather show no number than one that isn't really this company's.
Source:
greenhouse
· Checked Nov 20, 2026
Financial Intelligence
"These forward-looking statements include, but are not limited to, statements about:
•
our entrance into an Agreement and Plan of Merger (the "Merger Agreement") with Beacon Parent Holdings, L.P., a Delaware limited partnership ("Parent"), and Beacon Merger Sub, Inc., a Delaware corporation ("Merger Sub"), including our beliefs about the potential benefits of the transaction contemplated by the Merger Agreement; and the planned completion and timing of the transaction contemplated by the Merger A"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our entrance into an Agreement and Plan of Merger (the "Merger Agreement") with Beacon Parent Holdings, L.P., a Delaware limited partnership ("Parent"), and Beacon Merger Sub, Inc., a Delaware corporation ("Merger Sub"), including our beliefs about the potential benefits of the transaction contemplated by the Merger Agreement; and the planned completion and timing of the transaction contemplated by the Merger A"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"Business
Overview
We are a biotechnology company committed to commercializing potentially curative gene therapies for severe genetic diseases based on our proprietary lentiviral vector (“LVV”) gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"Generally Accepted Accounting Principles (“US GAAP”) in connection with the Company's accounting for lease arrangements, including certain arrangements with contract manufacturing organizations (“CMOs”) and a contract testing organization (“CTO”) that are deemed to contain one or more leases for accounting purposes."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
Source: SEC EDGAR · Retrieved Nov 21, 2026
Frequently Asked Questions About bluebird bio Manufacturing
What is bluebird bio Manufacturing's CDMO Signal Score?
bluebird bio Manufacturing has a Signal Score of 70/100, based on quality, operations, financial stability, and capacity data.
Evaluating bluebird bio Manufacturing for a manufacturing program?
Use the free AI matchmaker to compare bluebird bio Manufacturing against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 73.6
mRNA, Gene Therapy, Cell Therapy, Lentiviral
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score: 79.5
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
NecstGen
Leiden, NL
Signal Score: 78.1
AAV, Lentiviral, Cell Therapy
Compare bluebird bio Manufacturing with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.